Table 1.

Demographics and clinical characteristics at fingolimod treatment initiation

Characteristic	Total cohort (n = 275)	Prior interferon-β or glatiramer acetate (n = 169)	Prior NTZ (n = 83)	Naïve (n = 10)
Female (n (%))	179 (65.1)	114 (67.5)	52 (62.7)	5 (50.0)
Disease duration (year; median (IQR))	10.0 (9.0; n = 273)	10.0 (8.0; n = 167)	12.0 (7.0)*	4.5 (9.0)**
Age (year; median (IQR))	41.0 (12.0)	43.0 (14.0)	40.0 (11.0)	36.5 (11.0)
EDSS score (median (IQR))	3.0 (2.0; n = 150)	2.5 (2.0; n = 88)	3.5 (2.5; n = 48)	2.8 (2.5; n = 8)
Prior treatments (median (IQR))	2.0 (2.0)	2.0 (2.0)	3.0 (1.0)	N/A

Data regarding subgroups by prior therapy analysed the last therapy before switching to fingolimod. The 13 patients missing had previous treatments other than BRACE or natalizumab (off-label azathioprine (n = 4), mitoxantrone (n = 4), Ig IV (n = 4) and methotrexate (n = 1))

NTZ, natalizumab; N/A, not applicable; IQR, interquartile range; n, number of patients

*p = 0.021 compared with interferon-β or glatiramer acetate; **p < 0.05 compared with interferon-β or glatiramer acetate and NTZ